Insider filing · NBIX
Kevin Charles Gorman
Director
profile →
Neurocrine Biosciences, Inc.
NBIX · Healthcare · 59 filings in 24 months
ticker →
Kevin Charles Gorman sold $37.8M of Neurocrine Biosciences (NBIX)
Executed May 19, disclosed May 21, 2 days later.
Value, as filed
$37.8M
245,088 sh × $154.33
Executed
May 19
the trade date, as filed
Disclosed
May 21
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
KGKevin Charles Gorman (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Neurocrine Biosciences, Inc. (NBIX). The largest single filing was $37.8M of NBIX (245,088 sh × $154.33, as filed), executed May 19.
The name
NBIXHealthcare · Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunolog…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Kevin Charles Gorman in NBIX
NBIXSALE
Neurocrine Biosciences, Inc.
$13.4M106,322 sh × $126.41
Exec Aug 7 2025
Filed Aug 11 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $1.2M
9,613 sh × $120.38
Exec May 27 2025
Filed May 29 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $682K
5,844 sh across 2 lots
Exec Feb 13 2025
Filed Feb 14 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $269K
2,274 sh × $118.37
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $414K
2,707 sh × $152.92
Exec Jan 31 2025
Filed Feb 4 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $21.8M
146,105 sh × $149.46
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET